In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events

Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/day) in reducing cardiovascular events. Clinicians in Asia doubt...

Full description

Bibliographic Details
Main Authors:	Chaithiraphan, S (Author), Chen, JH (Author), Dans, AL (Author), Gao, P (Author), Jae-Hyung, K (Author), Jun, Z (Author), Liu, LS (Author), Teo, K (Author), Yusoff, K (Author), Yusuf, S (Author)
Format:	Article
Language:	English
Series:	PLOS ONE
Online Access:	View Fulltext in Publisher

In a subgroup of high-risk asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events

by Chaithiraphan, S., Chen, J.-H, Dans, A.L, Gao, P., Jae-Hyung, K., Lisheng, L., Teo, K., Yusoff, K., Yusuf, S., Zhu, J.

View Fulltext in Publisher
View in Scopus

Article

In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events

Similar Items